-
71.发明授权公开(公告)号：US10472401B2
公开(公告)日：2019-11-12
申请号：US15199270
申请日：2016-06-30
发明人： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： A61K38/00 , A61K35/12 , C07K14/47 , C07K14/74 , A61K39/00 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/6881 , G01N33/569 , C07K14/82 , C07K16/32 , C12Q1/6886 , G01N33/574 , C07K14/705 , C07K16/18
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
72.发明申请公开(公告)号：US20190336590A1
公开(公告)日：2019-11-07
申请号：US16502305
申请日：2019-07-03
发明人： Oliver Schoor , Andrea Mahr , Toni Weinschenk , Anita Wiebe , Jens Fritsche , Harpreet Singh
IPC分类号： A61K39/00 , C12N5/0783 , C07K14/725 , G01N33/574 , C12Q1/6886 , C12N15/115 , C07K14/47 , C07K16/30 , C07K14/74 , C07K14/705
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10464990B2
公开(公告)日：2019-11-05
申请号：US15602746
申请日：2017-05-23
发明人： Andrea Mahr , Toni Weinschenk , Anita Wiebe , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K14/74 , C07K7/06 , C07K16/28 , C07K14/725 , C12N15/115 , C12N5/0783 , A61K39/00 , G01N33/574 , C12Q1/6886 , G01N33/50 , C07K7/08 , C07K16/30 , A61K38/17 , C07K14/47 , C12N9/12
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10457712B2
公开(公告)日：2019-10-29
申请号：US15145999
申请日：2016-05-04
发明人： Oliver Schoor , Andrea Mahr , Toni Weinschenk , Anita Wiebe , Jens Fritsche , Harpreet Singh
IPC分类号： C07K14/47 , A61K39/00 , C07K14/74 , C07K16/28 , C12N5/0783 , C12N15/113 , C07K14/725 , C07K16/30 , A61P35/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10450357B2
公开(公告)日：2019-10-22
申请号：US16388925
申请日：2019-04-19
发明人： Colette Song , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
IPC分类号： A61K38/00 , C07K14/47 , A61P35/00 , C12N5/0783 , C07K16/30 , C12N15/10 , G01N33/574 , A61K39/00 , C12N15/115 , C07K14/74 , C07K14/725
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
76.发明授权公开(公告)号：US10383930B2
公开(公告)日：2019-08-20
申请号：US16100498
申请日：2018-08-10
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Müller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68 , A61K38/00
摘要： A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.
-
77.发明授权公开(公告)号：US10376569B2
公开(公告)日：2019-08-13
申请号：US16210357
申请日：2018-12-05
发明人： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： A61K35/17 , A61K39/00 , A61K38/17 , C07K7/06 , C07K14/47 , C07K14/725 , C12N15/115 , A61P35/02 , A61K38/08 , C07K16/28 , C07K16/00 , C07K14/72 , A61P35/00 , A61K38/00 , A61K39/39
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
78.发明授权公开(公告)号：US10364282B2
公开(公告)日：2019-07-30
申请号：US16281155
申请日：2019-02-21
发明人： Andrea Mahr , Toni Weinschenk , Colette Song , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： A61K39/00 , C07K14/74 , C07K14/635 , C07K14/47 , C07K16/28 , C07K14/725 , C12N5/0783 , C12Q1/6886 , G01N33/574 , A61K38/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10364281B2
公开(公告)日：2019-07-30
申请号：US16167656
申请日：2018-10-23
发明人： Annika Sonntag , Toni Weinschenk , Andrea Mahr , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K14/74 , G16B25/00 , A61K35/17 , A61K39/00 , C07K14/725 , C07K16/28 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , A61K38/04 , A61P37/04 , A61P35/00 , A61K38/17 , C07K7/06
摘要： A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
-
80.发明授权公开(公告)号：US10357551B2
公开(公告)日：2019-07-23
申请号：US15869471
申请日：2018-01-12
发明人： Toni Weinschenk , Jens Fritsche , Harpreet Singh , Andrea Mahr , Martina Ott , Claudia Wagner , Oliver Schoor
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
搜索结果
574 条记录 (耗时 0.07 秒)
